

Toolkit



#### **Contents**

Module 1 - Navigating Buprenorphine Prescribing for the Primary Care Physician	3
Module 2 - Substance Use Disorder and Patient Identification	4
Module 3 - Buprenorphine Medical Management: Monitoring the Patient	5
Module 4 - OBAT Eligibility, Intake and Assessment	6
Module 5 - Challenging Clinical Scenarios in MOUD: Early Refills and Lost or Stolen Medication	7
Module 6 - Patient Support for Induction and Maintenance	8
Module 7 - Complex Cases in Buprenorphine Treatment, Part 1	9
Module 8 - Operationalizing Team Meetings, Systematic Case Review, & Documentation	10
Module 9 - Complex Cases in Buprenorphine Treatment, Part 2	11
Module 10 - Team Roles and Responsibilities	12
Module 12 - Supporting the Patient Beyond Buprenorphine	14

#### Module 1 - Navigating Buprenorphine Prescribing for the Primary Care Physician

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Information Specific to Providers as Members of the Care Team	11-13

Resource (with link)	Brief Description
The Narcotic Farm	A documentary outlining the history of the federal prison/hospital in Lexington, Kentucky that was the first to treat drug addiction as a medical rather than a criminal problem.
Become a Buprenorphine Waivered Practitioner (SAMHSA)	Up-to-date information, provided by SAMHSA on requirements for buprenorphine prescribing.
DSM-5 Criteria for Substance	An article published in the American Journal of
<u>Use Disorders:</u>	Psychiatry that outlines major issues and evidence
Recommendations and	considered by the workgroup that drafted
<u>Rationale</u>	recommendations for the DSM-V criteria for substance
	use disorder.

#### Module 2 - Substance Use Disorder and Patient Identification

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Introduction to the Nurse Care Manager Model of OBAT	10
Goals of OBAT Treatment	18
Patient Initiation Roadmap	20
DSM-5 Checklist of Diagnostic Criteria: Opioid Use Disorder	179-180

Resource (with link)	Brief Description
AIMS (Advanced Integrated Mental Health Solutions) Center Implementation Guide - Create a Clinical Workflow	<ul> <li>This Implementation Guide was developed to support implementation of the Collaborative Care Model (CoCM).</li> <li>The Clinical Workflow Plan (linked under Implementation Resources) provides a worksheet care teams can use to document who, how, when, and where specific tasks are completed.</li> <li>While the tasks may be different, the framework may assist teams with clinical workflow development discussions.</li> </ul>
A Single-Question Screening Test for Drug Use in Primary Care	<ul> <li>A reference article about a single-question screening test for drug use and drug use disorders in primary care.</li> </ul>
Drug Abuse Screening Test (DAST-10)	<ul> <li>Information regarding the questions contained within the DAST-10.</li> </ul>
NIDA (National Institute on Drug Abuse)-Modified ASSIST	An interactive online screening tool for drug use in a general medical setting.
SAMHSA page on SBIRT	<ul> <li>Information from the Substance Abuse and Mental Health Services Administration regarding the SBIRT Model including general information, practice resources, and coding for reimbursement support.</li> </ul>
eCQM Specifications and Materials	Up to date information about electronic clinical quality measures.
MAPS (Michigan Automated Prescription System) User Support Manual	<ul> <li>Information regarding use of AWARxE, Michigan's Prescription Drug Monitoring Program.</li> </ul>
Washington State Agency Medical Directors' Group Opioid Dose Calculator	An online tool to assist with calculation of the total morphine equivalents per day.

#### Module 3 - Buprenorphine Medical Management: Monitoring the Patient

The following section of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> is relevant to this module:

Section	Page(s)
Monitoring, Retention, and Treatment Considerations – Toxicology Screening	62-63

Resource (with link)	Brief Description
Appropriate Use of Drug Testing in Clinical Addiction Medicine: A Consensus Statement	<ul> <li>A consensus statement from the American Society of Addiction Medicine that provides guidance on effective use of drug testing in the identification, diagnosis, treatment, and promotion of recovery for patients with, or at risk for, addiction.</li> <li>This resource is the primary reference for the content</li> </ul>
	outlined in module 3.

#### Module 4 - OBAT Eligibility, Intake and Assessment

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Candidates for OBAT	18
Goals of OBAT Treatment	18
Initial Screening Overview	20
OBAT NCM Intake Overview	21-22
OBAT Provider Visit Overview	22-23
Initial Screening Note Template	96-104
OBAT Nurse Intake Template	105-111
OBAT Treatment Agreement and Clinic Policies Overview	148-151
Sample OBAT Treatment Agreement (multiple languages	152-156

Resource (with link)	Brief Description
Motivational Interviewing:	A book that provides information and examples of the
Helping People Change, 3rd	motivational interviewing process.
Edition	
Motivational Interviewing in	A book that outlines tools to enhance communication
Health Care: Helping Patients	and patient engagement.
Change Behaviors (Applications	
of Motivational Interviewing)	
Books Recommended by MINT	A list of various books and workbooks on the topic of
(Motivational Interviewing	motivational interviewing.
Network of Trainers)	
<b>Building Motivational</b>	A motivational interviewing workbook that allows
Interviewing Skills: A	readers to work through sample dialogues, exercise
Practitioner Workbook	and practice opportunities.

# Module 5 - Challenging Clinical Scenarios in MOUD: Early Refills and Lost or Stolen Medication

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance +</u> (<u>OBAT TTA+</u>) are relevant to this module:

Section	Page(s)
Care Team Components	11-17
Treatment Initiation, Stabilization, and Maintenance (including medications beyond buprenorphine)	27-61
Monitoring, Retention, and Treatment Considerations	62-64
Evaluating and Revising the Treatment Plan	85-95
OBAT Treatment Agreement and Clinic Policies Overview	148-151
Sample OBAT Treatment Agreement (multiple languages	152-156

Resource (with link)	Brief Description
TIP 40: Clinical Guidelines for	Consensus- and evidence-based treatment guidance
the Use of Buprenorphine in the	for the use of buprenorphine from the Substance
Treatment of Opioid Addiction:	Abuse and Mental Health Services Administration
Treatment Improvement	(SAMHSA).
Protocol (TIP) Series 40 (2004)	Provides physicians with information they can use to
	make practical and informed decisions about the use
	of buprenorphine to treat opioid addiction.
ASAM National Practice	Evidence-based information on the treatment of
Guideline for Use of	opioid use disorder from the American Society of
Medications in the Treatment of	Addiction Medicine (ASAM).
Addiction Involving Opioid Use	
(2015)	
PCSS Guidance – Buprenorphine	Additional guidance (beyond what is provided in the
Induction (2013)	TIP 40 Guidelines) on buprenorphine induction from
	the Providers Clinical Support System (PCSS).
A Patient's Guide to Starting	Patient information on buprenorphine induction.
Buprenorphine at Home	

#### **Module 6 - Patient Support for Induction and Maintenance**

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Introduction to the Nurse Care Manager Model of OBAT	10
Candidates for OBAT	18
Goals of OBAT Treatment	18
Patient Initiation Roadmap	20
Treatment Initiation, Stabilization, and Maintenance (including medications beyond buprenorphine)	27-61
Buprenorphine Initiation Note Template	112-114
OBAT Nursing Follow-Up Note Template	115-119
Treatment Consent Forms	120-127
Pharmacotherapy for Managing Opioid Withdrawal	157
A Guide for Patients Beginning Buprenorphine Treatment	158-159
Clinical Tools: COWS Scale	181-182
Pharmacotherapy for Opioid Use Disorder	187-189

Resource (with link)	Brief Description	
Suboxone® Medication Guide	Contains important information about	
	buprenorphine/naloxone sublingual films.	
AIMS (Advanced Integrated	This relapse prevention plan was developed to support	
Mental Health Solutions) Center	patients with depression – general principles apply to	
Relapse Prevention Plan	relapse prevention planning for substance use	
	disorder.	
How to Create a Successful	An article that outlines all the components of a relapse	
Relapse Prevention Plan	prevention plan and how to craft one to support a	
	patient with substance use disorder.	

#### Module 7 - Complex Cases in Buprenorphine Treatment, Part 1

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Treatment Initiation, Stabilization, and Maintenance (including medications beyond	27-61
buprenorphine)	
Monitoring, Retention, and Treatment Considerations	62-84
Evaluating and Revising the Treatment Plan	85-95

Resource (with link)	Brief Description	
False-Positive Ethyl Glucuronide	An article from Forensic Science International that	
Immunoassay Screening Caused	describes false-positive DRI EIE EtG enzyme	
by a Propyl Alcohol-Based Hand	immunoassay results caused by propyl glucuronides in	
Sanitizer	urine after using a propanol-based hand sanitizer.	

# Module 8 - Operationalizing Team Meetings, Systematic Case Review, & Documentation

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Care Team Components	11-17
Initial Screening Note Template	96-104
OBAT Nurse Intake Template	105-111
Buprenorphine Initiation Note Template	112-114
OBAT Nursing Follow-Up Note Template	115-119

The following resources are also relevant to this module and may provide additional support:

Resource (with link)	Brief Description	
Using SBAR Communications in	An article from Home Healthcare Now that explores	
Efforts to Prevent Patient	why communication between team members can be a	
Rehospitalizations	challenge, introduces SBAR communication, analyzes	
	SBAR components, and provides templates and	
	examples.	
Professional Communication	A chapter on communication from Patient Safety and	
and Team Collaboration	Quality: An Evidence-Based Handbook for Nurses.	
	This chapter discusses the importance of effective	
	communication, barriers, and practice implications	
	(including SBAR and alternatives).	

NOTE: Refer to **SBAR Example – New Patient Case** handout.

#### Module 9 - Complex Cases in Buprenorphine Treatment, Part 2

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Treatment Initiation, Stabilization, and Maintenance (including medications beyond	
buprenorphine)	
Monitoring, Retention, and Treatment Considerations	62-84
Evaluating and Revising the Treatment Plan	85-95

#### **Module 10 - Team Roles and Responsibilities**

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Care Team Components	11-17

The following resources are also relevant to this module and may provide additional support:

Resource (with link)	Brief Description
Creating Patient-Centered Team-Based Primary Care	Information from the Patient-Centered Medical Home Resource Center about patient-centered team-based primary care.
AIMS (Advanced Integrated Mental Health Solutions) Center Implementation Guide - Create a Clinical Workflow	<ul> <li>This Implementation Guide was developed to support implementation of the Collaborative Care Model (CoCM).</li> <li>The Clinical Workflow Plan (linked under Implementation Resources) provides a worksheet care teams can use to document who, how, when, and where specific tasks are completed.</li> <li>While the tasks may be different, the framework may assist teams with clinical workflow development discussions.</li> </ul>
Care Coordination	Information about care coordination from the Agency for Healthcare Research and Quality.
Team-Based Care: Moving from Ideas to Action	A Q & A article from the Institute for Healthcare     Improvement focused on providing guidance to teams     interested in implementing team-based care.
Pain Guide	<ul> <li>An education and self-management resource developed by the University of Michigan in support of a patient-centric model of chronic pain care.</li> <li>This resource contains a symptoms and activity tracker based on the SPACE and ERASE concepts covered in this module.</li> </ul>
FAQs and Fact Sheets regarding Substance Abuse Confidentiality Regulations	<ul> <li>Information from the Substance Abuse and Mental Health Services Administration (SAMHSA) on confidentiality regulations related to treatment of substance use disorder, including 42 CFR Part 2.</li> </ul>

NOTE: Refer to Fillable Tasks and Roles Spreadsheet (click here if you intent to print the document)

#### **Module 11 - Pain and Addiction**

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Treatment Initiation, Stabilization, and Maintenance (including medications beyond	27-61
buprenorphine)	
Monitoring, Retention, and Treatment Considerations	62-84
Evaluating and Revising the Treatment Plan	85-95

#### **Module 12 - Supporting the Patient Beyond Buprenorphine**

The following sections of the <u>Office-Based Addiction Treatment Training and Technical Assistance + (OBAT TTA+)</u> are relevant to this module:

Section	Page(s)
Care Team Components	11-17
Injectable Buprenorphine (Sublocade®)	42-50
Naltrexone	53-61
Monitoring, Retention, and Treatment Considerations	62-84